Key facts
- Innoture’s last known valuation is $73.8M (Dec 2025).
- It has raised $20.2M; the latest was Later Stage VC ($8.0M) in Dec 2025.
- Notable investors include Innovate UK, Welsh Government, Ayawas Group, New Model Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Innoture
- ·The full record, as it builds
Funding rounds
No funding rounds for Innoture are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innoture
Developer of microneedles and microneedle patches designed to enhance treatments via our innovative microneedle technology. The company's products are small, cause minimal pain, and work by perforating the thin outer layer of the skin, allowing the medicine or vaccine to enter the body, enabling surgeons to effectively transport large molecule drugs.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2011
- Employees
- 9
- Website
- innoture.co/
- Ownership
- Privately Held (backing)
Innoture doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innoture shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innoture in its N-PORT filings yet. We sweep new filings monthly.